Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.
Future Oncol
; 16(36): 3107-3116, 2020 Dec.
Article
in En
| MEDLINE
| ID: mdl-32869649
ABSTRACT
Aim:
To update overall survival (OS) results from a previous network meta analysis comparing the relative clinical efficacy of epidermal growth factor receptor-targeted tyrosine kinase inhibitors (EGFR TKIs) for EGFR mutation positive (EGFR+) advanced non-small-cell lung cancer (NSCLC). Materials &methods:
A Bayesian network meta analysis was conducted using updated/mature randomized controlled trial OS results in response to first-line EGFR TKI therapies.Results:
Dacomitinib showed a numerical improvement of OS relative to other EGFR TKIs afatinib (hazard ratio [HR] 0.87; 95% credible interval [CrI] 0.61-1.24), erlotinib (HR 0.79; 95% CrI 0.44-1.42), gefitinib (HR 0.75; 95% CrI 0.59-0.95) and osimertinib (HR 0.94; 95% CrI 0.68-1.29).Conclusion:
Dacomitinib should be considered as a first-line treatment option for patients diagnosed with advanced EGFR+ NSCLC.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Protein Kinase Inhibitors
/
Quinazolinones
/
Lung Neoplasms
Type of study:
Clinical_trials
/
Diagnostic_studies
/
Prognostic_studies
/
Systematic_reviews
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2020
Type:
Article
Affiliation country:
Canada